USP Forms Elemental Impurities Advisory Group - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Forms Elemental Impurities Advisory Group


The US Pharmacopeial Convention (USP) has formed the Elemental Impurities Implementation Advisory Group and appointed members to the group from various regulatory agencies. The group will recommend implementations and general chapter adjustments to USP and will report to the Chemical Analysis Expert Committee.

According to USP, the Advisory Group was formed in accordance with the Bylaws of the USP Convention, which state, “The EVP–CEO may appoint advisory bodies to advance the work of the Council of Experts and the Convention and provide advice to staff on policy matters.” 

Dr. Roger Williams, EVP–CEO and Chair, Council of Experts, appointed the following members to the group:

  • Jon Clark, FDA
  • David Gaugh, GPhA
  • John Kauffman, FDA and ICH Q3D Rapporteur (current)
  • David Klug, IPEC–Americas
  • John Leighton, FDA
  • Robert Osterberg, USP Toxicology Expert Committee
  • John Punzi, CHPA
  • Mark Schweitzer, ICH Q3D Rapporteur (through Step 2)
  • Phyllis Walsh, NJPQCA 

USP will keep stakeholders informed through web postings on the Elemental Impurities Key Issues page, including summaries of the Advisory Group’s deliberations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here